ZA200201788B - Substituted 1,5-dihydropyrrol-2-on derivatives as NMDA receptor antagonists for the treatment of pain. - Google Patents

Substituted 1,5-dihydropyrrol-2-on derivatives as NMDA receptor antagonists for the treatment of pain.

Info

Publication number
ZA200201788B
ZA200201788B ZA200201788A ZA200201788A ZA200201788B ZA 200201788 B ZA200201788 B ZA 200201788B ZA 200201788 A ZA200201788 A ZA 200201788A ZA 200201788 A ZA200201788 A ZA 200201788A ZA 200201788 B ZA200201788 B ZA 200201788B
Authority
ZA
South Africa
Prior art keywords
dihydropyrrol
pain
derivatives
substituted
treatment
Prior art date
Application number
ZA200201788A
Other languages
English (en)
Inventor
Michael Przewosny
Hermann Poschenrieder
Hans-Dietrich Stachel
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of ZA200201788B publication Critical patent/ZA200201788B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
ZA200201788A 1999-08-06 2002-03-04 Substituted 1,5-dihydropyrrol-2-on derivatives as NMDA receptor antagonists for the treatment of pain. ZA200201788B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19936719A DE19936719A1 (de) 1999-08-06 1999-08-06 Substituierte 1,5-Dihydropyrrol-2-on-Derivate

Publications (1)

Publication Number Publication Date
ZA200201788B true ZA200201788B (en) 2003-08-27

Family

ID=7917172

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200201788A ZA200201788B (en) 1999-08-06 2002-03-04 Substituted 1,5-dihydropyrrol-2-on derivatives as NMDA receptor antagonists for the treatment of pain.

Country Status (25)

Country Link
US (1) US6642267B2 (no)
EP (1) EP1200402B1 (no)
JP (1) JP2003506437A (no)
KR (1) KR20020025214A (no)
CN (1) CN1378532A (no)
AR (1) AR028848A1 (no)
AT (1) ATE304530T1 (no)
AU (1) AU782435B2 (no)
BR (1) BR0013311A (no)
CA (1) CA2381033A1 (no)
CO (1) CO5200758A1 (no)
CZ (1) CZ2002441A3 (no)
DE (2) DE19936719A1 (no)
ES (1) ES2248104T3 (no)
HK (1) HK1046405A1 (no)
HU (1) HUP0201937A3 (no)
IL (1) IL147977A0 (no)
MX (1) MXPA02001212A (no)
NO (1) NO20020574L (no)
NZ (1) NZ516988A (no)
PE (1) PE20010402A1 (no)
PL (1) PL353854A1 (no)
SK (1) SK1702002A3 (no)
WO (1) WO2001010833A1 (no)
ZA (1) ZA200201788B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1269482C (zh) * 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US9072662B2 (en) 2004-03-29 2015-07-07 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
WO2006071274A2 (en) * 2004-12-23 2006-07-06 Voyager Pharmaceutical Corporation Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer’s disease
EP2792347A1 (en) 2005-09-28 2014-10-22 Auris Medical AG Pharmaceutical compositions for the treatment of inner ear disorders
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
JP5523107B2 (ja) 2006-11-30 2014-06-18 プロビオドルグ エージー グルタミニルシクラーゼの新規阻害剤
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
ES2533484T3 (es) 2007-04-18 2015-04-10 Probiodrug Ag Derivados de tiourea como inhibidores de la glutaminil ciclasa
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
DK2324126T3 (da) 2008-08-12 2014-06-16 Zinfandel Pharmaceuticals Inc FREMGANGSMÅDE TIL IDENTIFICERING AF Alzheimers SYGDOMSRISIKOFAKTORER
DK2475428T3 (en) 2009-09-11 2015-09-28 Probiodrug Ag Heterocyclic derivatives as glutaminylcyklaseinhibitorer
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
CN102791704B (zh) 2010-03-10 2015-11-25 前体生物药物股份公司 谷氨酰胺酰环化酶(qc, ec 2.3.2.5)的杂环抑制剂
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
UA114704C2 (uk) 2011-01-10 2017-07-25 Зінфандел Фармасьютікалз, Інк. Способи та лікарські засоби для лікування хвороби альцгеймера
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
KR102084185B1 (ko) 2013-08-29 2020-03-04 주식회사 대웅제약 테트라히드로사이클로펜타피롤 유도체 및 이의 제조방법
US10708389B2 (en) * 2016-12-06 2020-07-07 Intelligrated Headquarters, Llc Phased deployment of scalable real time web applications for material handling system
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL258360A (no) * 1960-11-25
GB2173499A (en) * 1985-02-04 1986-10-15 Ici Plc Fungicidal dithiolopyrrolones
GB2170498A (en) * 1985-02-04 1986-08-06 Ici Plc Processes for making fungicidal dithiolopyrrolones
GB9210393D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
HUP0201937A2 (en) 2002-10-28
NZ516988A (en) 2004-11-26
PE20010402A1 (es) 2001-05-05
ES2248104T3 (es) 2006-03-16
JP2003506437A (ja) 2003-02-18
CA2381033A1 (en) 2001-02-15
ATE304530T1 (de) 2005-09-15
NO20020574D0 (no) 2002-02-05
PL353854A1 (en) 2003-12-01
DE50011178D1 (de) 2005-10-20
HK1046405A1 (zh) 2003-01-10
CN1378532A (zh) 2002-11-06
AU6827900A (en) 2001-03-05
MXPA02001212A (es) 2002-07-02
EP1200402A1 (de) 2002-05-02
CZ2002441A3 (cs) 2002-05-15
AU782435B2 (en) 2005-07-28
AR028848A1 (es) 2003-05-28
US20020161033A1 (en) 2002-10-31
KR20020025214A (ko) 2002-04-03
IL147977A0 (en) 2002-09-12
BR0013311A (pt) 2003-01-28
NO20020574L (no) 2002-03-25
CO5200758A1 (es) 2002-09-27
DE19936719A1 (de) 2001-02-15
US6642267B2 (en) 2003-11-04
EP1200402B1 (de) 2005-09-14
HUP0201937A3 (en) 2002-12-28
SK1702002A3 (en) 2002-07-02
WO2001010833A1 (de) 2001-02-15

Similar Documents

Publication Publication Date Title
ZA200201788B (en) Substituted 1,5-dihydropyrrol-2-on derivatives as NMDA receptor antagonists for the treatment of pain.
MXPA03009644A (es) Grupos azabiciclicos sustituidos para el tratamiento de enfermedades.
HK1047580A1 (en) Dibenzopyrans as glucocorticoid receptor antagonists for treatment of diabetes.
ZA200201511B (en) 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents.
MXPA02001497A (es) Derivados de 3-(5)-ureido-pirazol, procedimiento para su preparacion y sus uso como agentes antitumorales.
ZA200203252B (en) Process for preparing 4"-substituted-9-deoxo-9A-AZA-9A-homoerythromycina derivatives.
PL363907A1 (en) Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain.
GB9911053D0 (en) 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
HK1072052A1 (en) 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists
AU2003265589A8 (en) Process for the preparation of 1,1,1,2,2-pentafluoroethane
PL356990A1 (en) Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists
HK1028399A1 (en) Cyclopentene derivatives useful as antagonists of the motilin receptor.
HUP0202736A3 (en) Substituted aromatic-ring compounds, process for producing the same, and pharmaceutical compositions containing them and use thereof
AU5497000A (en) Non-malignant disease treatment with ras antagonists
HK1045684A1 (en) Biphenyl derivatives as antagonists of the neurokinine-1 receptor.
HK1051692A1 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain.
IL147978A0 (en) Substituted pyrrolidin-2,3,4-trion-3-oxime derivatives useful as nmda-receptor antagonists
HK1042699A1 (en) N-triazolylmethyl-piperazine derivatives as neurokinin receptor antagonists.
IL139023A0 (en) Process for the preparation of 2,3,5-trimethyl-p- benzoquinone
ZA200108392B (en) Process for the preparation of substituted pyrimidines.
IL162188A0 (en) Process for the preparation of Ä1,4,5Ü-oxadiazepine derivatives
MXPA03001472A (es) Compuestos para el tratamiento de trastornos adictivos.
PL377292A1 (pl) Ulepszony sposób wytwarzania 1,3-podstawionych indenów
SI1200402T1 (sl) Substituirani 1,5-dihidropirol-2-on-derivati, ucinkoviti kot antagonisti NMDA-receptorja za tretiranje bolecinskih stanj
ZA200102818B (en) Process for the preparation of 4,4'-dihalogen-O-hydroxydiphenyl compounds.